On April 4 and 5, 2026, in Ho Chi Minh City, personnel from the Tropical Medicine Research Center for Talaromycosis (TMRC) attended an intensive training course on Good Clinical Practice (ICH-GCP). This serves as a vital preparation step for the upcoming launch of the LAmB-FAST international clinical trial.
(Figure 1. The scene prior to the ICH-GCP training session)
The training, organized by the Ministry of Health, was attended by Principal Investigators (PIs) and TMRC project staff. The program focused on two core pillars: ICH-GCP standards and safety reporting procedures in clinical trials.
The event was led by leading experts from the National Ethics Committee, including:
- Dr. Nguyen Ngo Quang: Director General of the Administration of Science, Technology and Training; Chief of Office of the National Ethics Committee.
- Assoc. Prof. Do Van Dung: Member of the National Ethics Committee.
- Dr. Vo Thi Nhi Ha: Member of the National Ethics Committee.
- Assoc. Prof. Nguyen Hoang Anh, PharmD: Member of the National Ethics Committee.
Updating ethical guidelines and safety reporting protocols is a mandatory requirement to ensure that research data generated in Vietnam meets global benchmarks and provides maximum protection for the rights and well-being of study participants.
TMRC is a collaborative project between Duke University (USA) and Pham Ngoc Thach University of Medicine, specializing in research on Talaromyces marneffei – an opportunistic pathogen with a high mortality rate in Southeast Asia. LAmB-FAST is a multi-center clinical trial designed to evaluate a treatment regimen using Liposomal Amphotericin B for patients with Talaromycosis. Compared to existing protocols, the study aims to minimize toxicity and significantly improve patient survival rates. The successful completion of this training session not only demonstrates TMRC’s operational readiness for LAmB-FAST but also reinforces the Center’s commitment to integrating Vietnamese medicine deeper into the global tropical disease research network.